Filament Health Corp. announced approval from the United States Food and Drug Administration (FDA) for a clinical trial at the University of California San Francisco's Translational Psychedelic Research Program. The investigator initiated trial will study the effects of PEX010, Filament's botanical psilocybin drug candidate, for the treatment of methamphetamine use disorder (MAUD).

MAUD is a growing public health emergency that is associated with serious health consequences. In the United States, the prevalence and mortality of MAUD has doubled over the past decade, yet available treatments have limited efficacy. PEX010 offers a possible breakthrough -- a single dose has been found to dramatically increase abstinence and reduce consumption in individuals with substance use disorders.

The goal of this trial will be to determine the safety, tolerability, and feasibility of psilocybin therapy for people living with MAUD.